Magdalena Yesil Biography and Net Worth

Director of Abiomed

Magdalena is a founder of Broadway Angels and the founding board member and first investor of Salesforce. She served on the board of Salesforce from inception to post IPO. She currently serves on the boards of Smartsheet (SMAR), Zuora (ZUO), SoFi and Informed. Magdalena has been active in Silicon Valley for three decades. Most recently, she spent eight years as a general partner at the venture capital firm US Venture Partners (USVP), making investments in a broad spectrum of technology startups. She has been an early investor in over 30 companies including theRealReal, PicsArt, Zuora, Socialcast (acquired by VMWare), Catch (acquired by Apple), Freshplum (acquired by TellApart and Twitter), Dotomi (acquired by ValueClick), 3Ware (acquired by AMCC), WebAction, Valicert (IPO), 128Technology, Securify (acquired by Kroll), iEscrow (acquired by eBay), and many others. Prior to her investing career, Magdalena was a serial entrepreneur, founding two successful electronic commerce companies, CyberCash — a pioneer in the secure electronic payment systems (IPO), and MarketPay, an embedded payments software company.

Magdalena was a pioneer in the commercialization of the Internet in its early days, helping it move out of the government and university domains and in establishing the infrastructure for e-commerce and financial transaction platforms. When her plan to purchase Internet access providers from universities would not get funded by venture capitalists, she joined UUnet (IPO), the first commercial Internet access provider. Magdalena was chosen Entrepreneur of the Year by Red Herring magazine. She started her career as a semiconductor design engineer at Advanced Micro Devices. She holds Bachelor of Science degrees in Industrial Engineering and Management Science and Engineering and a Masters of Science degree in Electrical Engineering, all from Stanford University.

What is Magdalena Yesil's net worth?: The estimated net worth of Magdalena Yesil is at least $5.15 million as of April 6th, 2021. Ms. Yesil owns 13,519 shares of Abiomed stock worth more than $5,151,009 as of November 18th. This net worth approximation does not reflect any other investments that Ms. Yesil may own. Learn More about Magdalena Yesil's net worth.
How do I contact Magdalena Yesil?: The corporate mailing address for Ms. Yesil and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected]. Learn More on Magdalena Yesil's contact information.
Has Magdalena Yesil been buying or selling shares of Abiomed?: Magdalena Yesil has not been actively trading shares of Abiomed in the last ninety days. Learn More on Magdalena Yesil's trading history.
Who are Abiomed's active insiders?: Abiomed's insider roster includes Marc Began (VP), Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

Magdalena Yesil Insider Trading History at Abiomed

Magdalena Yesil Buying and Selling Activity at Abiomed

Abiomed Company Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Today's Range

Now: $381.02

$381.02

50 Day Range

MA: $380.55

$377.20

$381.30

2 Week Range

Now: $381.02

$219.85

$381.99

Volume

258 shs

Average Volume

611,028 shs

Market Capitalization

$17.18 billion

P/E Ratio

65.47

Dividend Yield

N/A

Beta

1.4

❗ RSVP please!

From Behind the Markets | Ad

Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.

Just click here and secure your spot!